Wegovy® is a once-weekly injectable treatment licensed for weight management in adults with obesity or overweight with weight-related health conditions. It works by mimicking a natural hormone (GLP-1) that helps regulate appetite, reduce hunger, and support sustainable weight loss when combined with appropriate lifestyle changes.
Wegovy must be started at a low dose to minimise side effects, then gradually increased:
Week 1–4: 0.25 mg once weekly
Week 5–8: 0.5 mg once weekly
Week 9–12: 1.0 mg once weekly
Week 13–16: 1.7 mg once weekly
Week 17 onwards (maintenance): 2.4 mg once weekly
This step-up approach helps the body adjust and improves tolerability.
In clinical trials, patients using Wegovy alongside diet and lifestyle changes achieved significant weight reduction:
Up to 15% of body weight lost on average over 68 weeks
Many patients achieved >20% weight loss with consistent use and lifestyle adherence
Wegovy is currently one of the most effective medical weight-loss treatments available.
Wegovy may be suitable for adults who:
Have a BMI ≥30, or
Have a BMI ≥27 with a weight-related condition such as hypertension, prediabetes, or dyslipidaemia.
Reduces hunger and cravings
Helps control portion sizes
Supports healthier eating behaviours
Works alongside lifestyle changes for long-term results
